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Summary
Rationale: Variability in pulmonary disease severity is found in patients with cystic fibrosis (CF)
who have identical mutations in the CF transmembrane conductance regulator (CFTR) gene. We
hypothesized that one factor accounting for heterogeneity in pulmonary disease severity is
variation in the family of genes affecting the biology of interleukin-1 (IL-1), which impacts
acquisition and maintenance of Pseudomonas aeruginosa infection in animal models of chronic
infection. Methods: We genotyped 58 single nucleotide polymorphisms (SNPs) in the IL-1 gene
cluster in 808 CF subjects from the University of North Carolina and Case Western Reserve
University (UNC/CWRU) joint cohort. All were homozygous for ΔF508, and categories of
“severe” (cases) or “mild” (control subjects) lung disease were defined by the lowest or highest
quartile of forced expired volume (FEV1) for age in the CF population. After adjustment for age
and gender, genotypic data were tested for association with lung disease severity. Odds ratios
(ORs) comparing severe versus mild CF were also calculated for each genotype (with the
homozygote major allele as the reference group) for all 58 SNPs. From these analyses, nine SNPs
with a moderate effect size, OR ≤ 0.5or > 1.5, were selected for further testing. To replicate the
case-control study results, we genotyped the same nine SNPs in a second population of CF parent-
offspring trios (recruited from Children’s Hospital Boston), in which the offspring had similar
pulmonary phenotypes. For the trio analysis, both family-based and population-based associations
were performed. Results: SNPs rs1143634 and rs1143639 in the IL1B gene demonstrated a
consistent association with lung disease severity categories (P < 0.10) and longitudinal analysis of
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lung disease severity (P < 0.10) in CF in both the case-control and family-based studies. In
females, there was a consistent association (false discovery rate adjusted joint P-value < 0.06 for
both SNPs) in both the analysis of lung disease severity in the UNC/CWRU cohort and the family-
based analysis of affection status. Conclusion: Our findings suggest that IL1β is a clinically
relevant modulator of CF lung disease.
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INTRODUCTION
Cystic fibrosis (CF) results from mutations in both alleles of the cystic fibrosis
transmembrane conductance regulator (CFTR) gene. However, none of the 1,521 mutations
in CFTR identified thus far produces a predictable respiratory disease phenotype in CF
patients, although homozygosity for certain alleles usually gives rise to more severe
pulmonary disease. We hypothesized that one factor accounting for heterogeneity in
pulmonary disease severity is variation in the family of genes related to the function of
interleukin-1 (IL-1), which in an animal model of chronic lung infection1 was shown to
affect acquisition and maintenance of Pseudomonas aeruginosa infection, the major cause of
morbidity and mortality in CF. Lack of functional CFTR has been shown to affect a number
of responses within the lung whereby an ineffective innate immune response allows
organisms, particularly P. aeruginosa, to establish a chronic infection. Chronic P. aeruginosa
within the airway in CF patients is a well-known determinant of prognosis,2 with several
studies demonstrating associations between P. aeruginosa colonization and lung function
decline.3,4
Five components of the IL-1 R type I pathway may have implications for resistance to P.
aeruginosa lung infection and might also be involved in modulating airway inflammation
and subsequent lung function decline: the receptor itself, the proinflammatory cytokines
IL-1α (gene IL1A) and IL-1β (gene IL1B), the anti-inflammatory cytokine IL1-RA (gene
IL1RN), and the IL-1 type II receptor IL-1R1 (gene IL1R1).5–9 Certain genetic variations
within the IL-1 gene family can affect the expression and function of its gene products.10–14
Recent studies have shown the IL-1 gene family to be an important participant in
inflammatory signaling within the airway; both cultured human lung epithelial cells and the
lung epithelium of mice homozygous for mutant or missing CFTR alleles fail to rapidly
translocate nuclear factor kappaB (NF-kB) to the nucleus within 15 minutes of acute P.
aeruginosa infection, a process that is critical for effective immunity to P. aeruginosa and
which normally occurs in the presence of WT-CFTR alleles.15 IL-1R knockout mice
developed chronic lung infection with P. aeruginosa following infection via drinking water,
which also occurs with transgenic CF mice.16 Furthermore, cultured human airway
epithelial cells from a ΔF508 CFTR homozygous patient released considerably less IL-1β in
response to P. aeruginosa compared to the same cells transfected with a functional copy of
WT-CFTR.1 These studies suggest a relationship between IL-1 responses and CFTR-
dependent innate immune resistance to P. aeruginosa infection that could affect lung disease
severity in CF. Therefore, we focused our analysis on the IL-1 gene family because these
studies have shown it to be an important participant in the innate immune response in the
presence of wild-type (WT)-CFTR via activating signaling through the interleukin-1
receptor (IL-1R), which modulates the pulmonary immune response to P. aeruginosa
infection.1
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In view of the important role of the IL-1 family gene cluster in the early response to P.
aeruginosa (which is also affected by CFTR genotype) and the potential role of the IL-1
family in lung pathology, we sought to establish whether an association exists between
variations in specific genes within the IL-1 cluster of genes and lung disease severity in CF
patients. We found that polymorphisms in the IL-1 gene cluster in CF patients were
associated with the severity of lung disease, implicating a contribution of genetic variation
in these genes in the pathogenesis of lung function decline in CF.
METHODS
Study Populations
University of North Carolina and Case Western Reserve (UNC/CWRU) Cohort
—For this case-control study, weused the DNA and serum samples acquired by Michael
Knowles, MD (UNC/CWRU) and Mitch Drumm, PhD, from 840 patients with CF, enrolled
from 44 centers, who were initially determined to be homozygous for the ΔF508
genotype.17 The diagnosis of CF was documented in the medical record by the pilocarpine
iontophoresis sweat test (sweat chloride > 60 mmol/L). The 840 patients initially enrolled
were chosen because their forced expiratory volume in 1 sec (FEV1) measurements were in
the lowest quartile or highest quartile for age among ΔF508 homozygotes; of these, the lung
function of 275 patients was classified as severely impaired (lowest quartile) and that of 565
patients as mildly impaired (highest quartile). Pulmonary function classifications are
previously described by Schluchter et al.18 who define the mild CF patients as those who
survived until 15 years of age and had an FEV1 categorization consistent with mild CF lung
disease. Severe patients are defined only as young as 8 years of age because of the need for
at least 3 years of pulmonary function testing. Quartiles were defined by the Cystic Fibrosis
Foundation registry data classification of pulmonary function testing for the UNC center
when compared to US CF centers19,20 allowing for CF-specific lung function classification.
Because FEV1 is most predictive of survival in CF, it was used as the outcome for
phenotype–genotype analysis.21 Furthermore, FEV1% predicted was the outcome
measurement for phenotype-genotype analysis in both the UNC/CWRU screening
population and in the validation cohort, Children’s Hospital Boston (CHB) (as below), for
consistency among CF genetic modifier studies.17 The FEV1 measurement was defined as
percent predicted obtained from multiple FEV1 measurements acquired during the previous
5 years (prior to enrollment) using a mixed model analysis as defined by Schluchter and
colleagues.22 The FEV1 measurement was obtained when the patient was clinically stable
and not during a bronchitic exacerbation, defined as an FEV1 change of greater than 15%
predicted. A total of 32 patients were excluded because they had inadequate spirograms (2
patients), were found not to be homozygous for the ΔF508 genotype on a subsequent
evaluation (8 patients), or did not achieve more than 90% probability of being congruent
with others in the severe or mild category. There were 808 patients in the final data set. No
patient was excluded because of race or ethnic background; 96.7% of the patients were
identified as Caucasian. Further description of this cohort can be found in the publication by
Drumm and colleagues.17
Children’s Hospital Boston (CHB) Cohort—To attempt to replicate the results of the
case-control study using a different method of analysis and measurement of effect, we
genotyped the single nucleotide polymorphisms (SNPs) in a second population of CF
patients from CHB using a family-based design. All CF probands were registered in a
clinical and laboratory database and followed at CHB from 1993 to 2005. The diagnosis of
CF was documented in the medical record by the pilocarpine iontophoresis sweat test (sweat
chloride > 60 mmol/L) and/or the presence of two CFTR mutations. Over 90% of the CF
patients were evaluated in the CF clinic at least once per year. The yearly visits were
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prospectively scheduled annual visits where clinical evaluation was performed and
laboratory data obtained to include pulmonary function testing, sputum culture, and serum
laboratory measures.
We evaluated 126 trios (ascertained by the proband) with a pulmonary phenotype similar to
that used in the UNC/CWRU cohort, as described by Drumm and colleagues.17 We
identified eligible CF patients and collected laboratory data from the clinical laboratory
database at CHB. Specifically, for pulmonary function testing, microbiologic and genotype
data were extracted and downloaded into an ORACLE database. A structured query
language reporting tool was run to join the hospital-wide laboratory values requested to the
CF patient population followed at CHB. In the CHB cohort, we had multiple laboratory and
pulmonary function measurements spanning 13 years and were able to analyze the patients’
PFT measurements in both categorical and longitudinal analyses. For the categorical lung
function analysis, each patient’s FEV1 value was assigned a disease severity group based on
FEV1 values using the ESCF classification for patients in four age groups: 6–12 years
(severe, FEV1 ≤ 88.7% predicted; moderate, > 88.7–94.5%; mild, > 94.5–99.0%; very mild/
normal, > 99.0%); 13–17 years (severe, FEV1 ≤ 76.5% predicted; moderate, > 76.5–81.1%;
mild, > 81.1–87.7%; very mild/normal, > 87.7%); 18–29 years (severe, FEV1 ≤ 58.1%
predicted; moderate, > 58.1–63.9%; mild, > 63.9–70.7%; very mild/normal, > 70.7%); and >
30 years (severe, FEV1 ≤ 45.5% predicted; moderate, > 45.5–50.9%;mild, > 50.9–59.8%;
very mild/normal, > 59.8%).19,20 For the analysis, a child aged 12.9 would have an age of
12, because we used a “floor” statistical function that rounds the age down to the integer. CF
patients in the very mild/normal and the mild severity group were pooled for analysis and
compared to moderate and severe disease groups, which were also combined. Methods for
ascertaining sputum culture in the CHB cohort included both deep throat and sputum
cultures. Colonization was defined as one positive microbiologic growth on culture. Given
the method for extracting data from various electronic sources and merging them, it was not
possible to obtain symptom history or medication information. However, as UNC/CWRU
and CHB are accredited CF Care Centers, patients received standard CF care as outlined by
the CF Consortium guidelines, and detection and eradication regimens for P. aeruginosa
infection were similar. Most patients did not receive anti-staphylococcal prophylaxis. Anti-
Pseudomonas antibiotics were routinely given to patients with two positive CF cultures
(either documented by deep throat cultures or sputum culture) in an attempt to eradicate P.
aeruginosa. Approval by the Institutional Review Board was obtained and we received
informed consent from all subjects in the cohorts.
CFTR Genotyping
Genomic DNA isolated from each subject was evaluated for the presence of any of 1,500
CFTR gene mutations (Genzyme, Cambridge, MA or Ambry Genetics, Aliso Viejo, CA) as
part of clinical evaluation.
SNP Genotyping
We investigated the IL1-gene cluster (gene IL1A, gene IL1B, gene IL1RN, and gene IL1R1)
on chromosome 2, based on the National Center for Biotechnology Information (NCBI)
dbSNP build 127 (refer to Supplementary Appendix Table for information regarding rs ID,
alleles, minor allele frequency, HWE, and SNP function). We genotyped 58 SNPs in the
IL-1 gene cluster in 808 CF subjects from UNC/CWRU cohort. SNPs in candidate genes
were selected for genotyping on the basis of one of three criteria: r2 value of at least 0.7 (for
linkage disequilibrium [LD]-tagging SNPs), allele frequency of at least 10% in European-
American populations, and/or causing a non-synonymous alteration in the amino acid
sequence of the coded protein. All SNPs were verified by review of documentation in
several databases—dbSNP, the Innate Immunity (http://innate.immunity.-net/SNPper)
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(http://snpper.chip.org/), and Seattle SNPs (http://pga.mbt.washington.edu) program for
genomic applications (PGA) web sites. SNP genotyping was performed using the standard
protocol for the iPLEX assay on a Sequenom MassARRAY MALDI–TOF mass
spectrometer23 (Sequenom, San Diego, CA) or TaqMan assays24 (Applied Biosystems,
Foster City, CA).
Association Analysis
Single SNP association analyses were conducted using logistic regression for dichotomous
outcomes and linear regression for continuous phenotypes. All population-based statistical
analyses were performed using SAS statistical software (SAS Institute, Inc., Cary, NC),
where all family-based association testing was performed using FBAT25 and PBAT.26 In the
two cohorts, we evaluated a potential association between IL1 polymorphisms and lung
function in CF in the following way. In the screening step, we tested for association between
the selected SNPs and lung disease severity using extremes of pulmonary function
measurements, as defined by Drumm and colleagues, in a case-control analysis in the UNC/
CWRU CF subjects.17 In the replication cohort (CHB), we tested for association with
affection status (an allele transmission distortion) as defined by the ascertainment of the
proband in a family-based analysis using the FBAT approach. As a secondary analysis, we
also used the qualitative lung phenotype, with severity defined using extremes of pulmonary
function measurement determined by ESCF classification in a family-based analysis.27
Additionally, since quantitative lung function data were available in the CHB cohort, we
evaluated the association between the selected SNPs and lung function in a longitudinal
analysis, incorporating quantitative pulmonary function measurements over the first five
study visits. Only the first five annual study visits were included to minimize the number of
missing subjects (data completeness > 90% over the first five study visits) and minimize any
potential cohort effect. The longitudinal analysis was conducted in SAS (version 9.1) using a
mixed model with fixed effects for the SNP, subject age at baseline, and time under study.
Random intercepts and slopes were modeled for each subject. The UNC/CWRU cohort had
greater power to detect an association due to sample size and was used to screen SNPs while
the smaller cohort (CHB) was used to test for replication. This process is the validated
standard for analysis in genetic studies. We used the odds ratio (OR) and estimation of effect
to screen 58 SNPs for those 9 SNPs we would evaluate in the smaller cohort. Nine SNPs
were tested in the second cohort based on the OR because testing of all 58 SNPs would have
diluted the power to detect any signal due to the multiple comparisons problem. In
summary, we evaluated two CF populations (UNC/CWRU and CHB) and three phenotypes
—analysis of extremes of lung function using dichotomized lung function severity (in UNC/
CWRU and CHB cohorts), affection status/transmission distortion (CHB cohort), and
longitudinal lung function measures (CHB cohort) to assess whether the IL-1 family gene
cluster has an effect on CF lung disease.
University of North Carolina (UNC/CWRU) Cohort Analysis
Analysis of Extremes of Lung Function in UNC/CWRU Cohort—SNP
characteristics (allele frequency and Hardy-Weinberg equilibrium) for each SNP were
assessed. Selected SNPs in candidate genes were genotyped in 808 ΔF508 homozygotes
with “severe” or “mild” lung disease, as defined by the lowest or highest quartile of FEV1
for age. We tested for association between the selected SNPs and lung disease severity in
subjects with “mild” (n = 545) and “severe” (n = 263) illness by both Fisher’s exact and
Armitage trend testing. Multivariable associations between individual SNP and FEV1
percent predicted in the presence of potential confounders (age and gender) were tested
using a general linear model. Genotypes were coded assuming an additive genetic model.
For complex trait statistical models in which two or more loci may be involved in disease
susceptibility, additive models, in which the allele-specific risks of disease are associated
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with the multilocus genotypes across different loci, can be modeled as sums of factors for
each genotype at each locus. ORs comparing severe versus mild CF were also calculated for
each genotype (with the homozygote WTas the reference group) for all 58 SNPs, to
determine whether significant Fisher’s exact and Armitage tests corresponded to a clinically
meaningful change in the odds of severe CF. OR testing was conducted to assess the
magnitude of effect and examine the effect of each genotyped on risk, without imposing any
assumptions about the genetic model. Armitage tests with P < 0.05 have a 95% confidence
intervals that do not include 1. A false discovery rate (FDR) correction was applied to the
UNC cohort accounting for the 58 SNPs originally tested.28 From these analyses, nine SNPs
with OR ≤ 0.5 or > 1.5 showing evidence of association and moderate effect sizes were
selected for further testing in subjects recruited from CHB.
Children’s Hospital Boston (CHB) Cohort Analysis
Affection Status Analysis (Transmission Distortion)—For the familial data (CHB),
nine SNPs were tested using an additive model for evidence of association with the
diagnosis of CF in the proband. The purpose was to determine whether any of the SNP
alleles was significantly over- or under-transmitted to the proband.
Analysis of Extremes of Lung Function in CHB Cohort—We tested for association
between the selected SNPs and lung disease severity in subjects with “mild” or “severe”
illness as defined by an assigned disease severity group, based on FEV1 values and using the
ESCF patient classification for patients (described in Methods). Due to the small sample size
in the CHB cohort, we were unable to analyze the subjects in any of the four “extreme”
categories of normal/mild or moderate/severe lung impairment. Thus, the ESCF
classification was collapsed into two categories: normal/mild and moderate/severe. In the
CHB family analysis, P-values were obtained from an FBAT statistic comparing observed to
expected allele transmission from parents to CF probands with normal/mild or moderate/
severe lung function impairment at the first study visit.
Longitudinal Analysis of FEV1% Predicted in the CHB Cohort—Longitudinally
measured lung function phenotypes were available in this cohort. As some of the
associations observed in the UNC/CWRU cohort displayed differential effects by gender,
both overall and gender-stratified analyses were conducted.
To maximize the power to detect an association, we analyzed percent-predicted FEV1 with a
multivariate population-based analysis (the offspring genotype, rather than parent–child
allele transmissions, was the predictor of interest). A mixed model (SAS) was fit, including
a random effect for each subject and for time since recruitment. Each SNP was tested
separately, assuming either an additive, dominant, or recessive genetic model as a fixed
effect, along with age at recruitment, gender, and time since recruitment. As the ΔF508
mutation in the CFTR gene is the most common cause of CF in the Caucasian population,
the analysis was repeated with adjustment for the presence or absence of two copies of
ΔF508 alleles using a recessive genetic model.
Finally, we examined the relationship between the two SNPs of interest, rs1143634 and
rs1143639, and the presence of non-mucoid or mucoid P. aeruginosa in the CHB cohort.
Methods for ascertaining culture included both deep throat and sputum cultures.
Colonization was defined as one positive microbiologic growth on culture. Two sets of
analyses were conducted. Initially, logistic regression models were fit to determine whether
rs1143634 or rs1143639 genotypes predicted the presence or absence of non-mucoid or
mucoid P. aeruginosa, after adjusting for age at first study visit. Second, survival analyses
(also adjusting for age at first study visit) were performed to test whether specific rs1143634
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or rs1143639 genotypes predicted time of onset of non-mucoid or mucoid P. aeruginosa.
The analysis was conducted using a Cox-proportional hazards model fit (using proc phreg in
SAS) to test this hypothesis in both the overall group and gender-stratified groups.
RESULTS
Population Baseline Characteristics
A total of 808 UNC/CWRU subjects were analyzed (Table 1). The mean age for 263
patients classified with severe lung disease was 16.2 ± 4.1 years, and the mean age for 545
patients classified with mild lung disease was 28.6 ± 9.7 years (Table 1). Males made up
49.4% of the severe disease group and 55.6% of the mild disease group. All of the analyzed
patients were ΔF508 homozygous and therefore pancreatic-insufficient. Over 80% of the
cohort had positive cultures for P. aeruginosa. The mean FEV1% predicted was 46.6 ±16.1
in the severe group and72.4 ± 28.1 in the mild group. The reported rate of FEV1 decline
(percent/year) in the severe group was 3.65 ± 2.20 and 1.35 ± 1.51 in the mild group.17
In the replication cohort from CHB, a total of 126 trios were analyzed, with a mean age of
10 ± 6.46 years for the CF patients when the first clinical values were analyzed (Table 2).
This cohort was 53% male and 47% female. Forty-one percent of the patients were AF508
homozygous and 40% were heterozygotes. The other 12% of the CFTR mutations included
G551D, G542X, G85E, W1282X, and N1303K. Ninety-five percent of the cohort were
pancreatic-insufficient, and 92% had positive cultures for P. aeruginosa, of which 70% were
positive for mucoid P. aeruginosa. The mean predicted rate of decline in FEV1 was −2.29
±3.76 (percent/year), consistent with an average decline in FEV1 percent predicted of 2.5–
2.6 (percent/year) for CF patients.18 Table 3A illustrates the pulmonary function data
available for the 126 CF subjects obtained stratified by age. Table 3B illustrates the
pulmonary function data for the 126 CF subjects obtained at the first five clinical visits and
stratified by age. In Table 3B, there is a value for each subject per year. For example, if a
subject had data each year from the age of 11–14, the subject was represented four times in
the table. They were represented twice in the 6–12 age category and twice in the 13–17 age
category.
We confined our analyses to self-described Caucasians to minimize the chance of
identifying false associations due to population stratification in the case-control analysis. In
addition, power to detect associations in other racial groups is low due to small sample sizes,
particularly in CF, where the affected cohort is overwhelmingly Caucasian.29
Genotyping Quality Control
A total of 58 SNPs in the IL-1 gene cluster were initially investigated in the UNC/CWRU
cohort;9 SNPs were then investigated in the CHB cohort. Across both cohorts, none of the
selected SNPs showed significant overall departure from Hardy-Weinberg equilibrium.
Genotyping quality for both Sequenom and TaqMan assays was high, with an average
completion rate of 98%, no discordances on repeat genotyping of a random 10% of the
cohort, and a low rate of Mendelian inconsistencies.
Associations Between IL-1 SNPs and Lung Function
Results From the University of North Carolina (UNC/CWRU) Cohort
Analysis of extremes of lung function: We tested for an association between the selected
SNPs and lung disease severity in subjects with “mild” (n = 545) or “severe” (n = 263)
illness by Fisher’s exact and Armitage trend testing. As shown in Table 4, three SNPs in the
gene for IL1-β (IL1B), rs1143633, rs1143639, and rs3917356, as well as a SNP in IL1-RN
(the gene for the receptor antagonist for IL-1), rs4252019, were suggestive of an association
Levy et al. Page 7













with lung disease severity in CF (P < 0.10). While not significant in the non-stratified
analysis, when stratified by gender, other SNPs were associated with lung disease severity:
another SNP, rs17561, in the gene for IL-1 α (IL1A) (P < 0.05 in the males), one SNP in the
IL1B gene rs1143634 (P < 0.07 in the females), and one SNP rs2228139 in the IL1-R1 gene
(P < 0.05 in the females). To further determine which SNPs to genotype in a family-based
analysis, we fit a logistic regression model for each SNP, calculating the odds of severe
versus mild CF for each genotype in all 58 SNPs initially screened. The analysis with the
logistic regression models confirmed the Armitage testing. Eight SNPs showed an OR > 1.5
(rs 17561, 3917356, 1143633, 1143634, 1143639, 3917368, 2228139, and 4252019),
indicating greater odds of having severe versus mild CF lung disease when comparing
genotyping categories (data not shown). For an OR > 1, the genetic variant is associated
with disease and in this case worse pulmonary function. One SNP, rs2071374 in the gene for
IL-1 α (IL1A), had an OR ≤ 0.5 indicating greater odds of having mild CF lung disease
when comparing genotyping categories. With these promising results, we proceeded to
evaluate nine SNPs using a family-based analysis in a second population.
Results From the CHB Cohort
Affection status analysis (transmission distortion): We next evaluated 126 trios in a
second population of CF patients from CHB using a family-based design. For the familial
data (CHB), nine SNPs were tested using an additive model for evidence of association with
the diagnosis of CF in the proband (Table 5). Due to the gender-specific differences
observed for SNPs selected from the UNC/CWRU sample for replication, the association
analysis of affection status in the CHB cohort was conducted in both the overall and gender-
stratified cohort. Under an additive model, two of the SNPs associated with the IL1B gene,
rs1143634 and rs1143639, were suggestive of an association in the gender-stratified analysis
(P > 0.05). SNPs 1143634 and rs1143639 are in strong LD between the two markers (D =
−0.171, D′ = 1.0, and R2 = 0.98). None of the other seven SNPs was nominally significant
(all P > 0.05) in either the overall or stratified cohort.
As shown in Table 5, in the subgroup analysis, the P-values for the females are significant
(P < 0.05), demonstrating a strong effect size, given the small number of informative trios in
the CHB cohort (the number of informative trios for females was 29 for both SNPs). The
direction of the association is consistent across the UNC/CWRU and CHB cohorts; the
frequency of the minor allele is overrepresented in the UNC/CWRU severe CF cases (Table
4) and over-transmitted to female probands in the CHB cohort (Table 5). Therefore, the
association is suggestive, given the consistency across studies and the relatively small
number of female subjects (n = 366 in UNC/CWRU and informative trios = 29 in CHB),
and P-values (P < 0.10).
Given the consistent association in females (we have demonstrated a consistent effect across
cohorts), the P-values for rs1143634 and rs1143639 from Fisher’s test of association in the
UNC/CWRU cohort and P-values from the family-based association test in the CHB cohort
were combined using Fisher’s combined probability test. The joint P-values for SNPs
rs1143634 and rs1143639 from the overall test of association for the two studies, as well as
the analysis in males, were not significant. For females, the unadjusted joint P-values were
0.0086 and 0.0052 for rs1143634 and rs1143639 SNPs, respectively. After a FDR correction
was applied to the UNC/CWRU cohort, accounting for the 58 SNPs initially tested,28 the
adjusted P-values were 0.059 (rs1143634) and 0.052 (rs1143639). While this does not meet
significance at the strict α = 0.05 level, these are suggestive given the small sample size in
the female cohort. We report the P-value > 0.05 as evidence of a consistent association with
lung disease severity because the analysis is exploratory and is nonetheless worthwhile to
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report. There is replication in a second cohort, even with smaller power, and it has the same
effect direction.
Analysis of extremes of lung function in the CHB cohort: We also evaluated a
dichotomous phenotype in the CHB cohort, based on FEV1 ESCF categories, similar to the
categorization of the UNC/CWRU cohort. To maximize information from an increased
sample size that has fewer quantitative measures, the UNC/CWRU analysis compared
extremes of lung function, that is, severely impaired (lowest quartile) with mildly impaired
(highest quartile). For the CHB family data, which are from a smaller sample than the UNC/
CWRU cohort but include additional longitudinal quantitative FEV1 measurements, P-
values were obtained from an FBAT statistic comparing observed to expected allele
transmission from parents to CF probands with collapsed ESCF categories of normal/mild or
moderate/severe lung function impairment. There was no association in either the overall or
gender-stratified analysis in the CHB cohort (data not shown). However, this may be due to
the small sample size, particularly in the gender-stratified analysis. For the females, 37
children were classified as normal/mildly impaired, 14 were classified as moderately/
severely impaired, and 8 were missing an FEV1 measurement. For the males, these numbers
were 35, 14, and 18, respectively (summing to 126 children/trios). The number of
informative families in each analysis ranged from 55 (in the overall analysis) to 23 (in the
gender-stratified analysis for females).
Longitudinal analysis of FEV1% predicted in the CHB cohort: To extract the most
information from our cohort, we also conducted a population-based longitudinal analysis.
Due to the unavailability of comparable longitudinal lung function data in the UNC/CWRU
cohort, additional analyses of lung function could be conducted only in the CHB cohort. The
two SNPs of interest in the IL1B gene from the affection status analysis, rs1143634 and
rs1143639, were tested for association using the FEV1% predicted phenotype, measured at
the first five study visits.
Figures 1a,b (confidence intervals not shown) and 2a,b (confidence intervals drawn) present
the age- and gender-adjusted means for FEV1% predicted for each genotype for IL1B SNPs
rs1143634 and rs1143639. The average length of time from the first study visit to the second
study visit was 1.4 years, and the mean length of time between subsequent visits was 1 year.
The mean length of time over all five study visits was 4.5 years. The calculated means are
limited to subjects with complete data for the first five study visits, to limit any potential
cohort effects. Displayed above each study visit (on the x-axis) are the corresponding
univariate effect size estimates and P-values for each genotype group. The beta estimates
represent the mean change in FEV1% predicted at each time point, for the AG/AA [CT/TT]
genotype in comparison to the GG [CC] genotype, after adjustment for age and gender. The
P-values are obtained from a Wald test, which tests the hypothesis that beta is equal to 0 at
each of the time points separately. When evaluating all five time points in a multivariate
analysis (Table 6), there is a marginally significant statistical difference in the FEV1%
predicted in subjects with one or two copies of the minor A or T allele for rs1143634 or
rs1143639, respectively. In the overall group, for rs1143634, the mean difference in FEV1
between the GG and AG/AA genotype groups across the five study visits was 5.6% after
adjusting for age and gender (P = 0.06). For rs1143639, the mean difference in FEV1
between the CC and CT/TT genotype groups across the five study visits was 6.7% after
adjusting for age and gender (P = 0.05). We would expect similar results for these two SNPs
because of the strong LD between the two markers (D = −0.171, D’ = 1.0, and R2 = 0.98).
The longitudinal model was adjusted for age at the first visit as well as time in follow-up to
reflect the variable ages and to account for the effect of age on FEV1. Age was not
significant across the different genotype groups. We also analyzed the means by genotype
(homozygote major allele vs. heterozygote and homozygote minor combined) and t-tests of
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the difference in ages (at each study visit) across groups. None of the differences were
significant (data not shown).
Table 6 presents the multivariate results for the dominant model, adjusting for age and
gender in the overall group, and for age in the gender-stratified analysis. There is a trend
toward decreasing FEV1% predicted for the heterozygote or homozygote minor allele. The
overall P-value (a test of whether the mean FEV1% predicted differs across the major allele
homozygotes vs. the heterozygotes and minor allele homozygotes combined) was 0.06 for
SNP rs1143634 and 0.05 for SNP rs1143639. Therefore, in the longitudinal analyses, having
one or two copies versus none of the minor allele shows evidence of association (P < 0.10)
for both of the SNPs within the IL1B gene and lung function decline. The analysis of the
CHB cohort was repeated with adjustment for ΔF508 alleles, assuming a recessive genetic
model. The presence of ΔF508 mutations was not associated with FEV1% predicted and did
not affect the relationship between SNPs rs1143634 or rs1143639 and FEV1% predicted.
The magnitude of the effect size estimates and P-values for SNPs rs1143634 and rs1143639
did not substantially change after inclusion of ΔF508 in the model (data not shown).
Finally, in an exploratory analysis, we examined the relationship between the two IL1B-
associated SNPs of interest, rs1143634 and rs1143639, and the presence of non-mucoid or
mucoid P. aeruginosa. Neither the logistic regression analyses nor the Cox model showed a
relationship between rs1143634 or rs1143639 genotypes and the presence or onset of
mucoid Pseudomonas (data not shown). There was no significant association between the
SNPs and presence of non-mucoid P. aeruginosa. However, in the overall (non-stratified)
analysis, for both rs1143634 and rs1143639, the presence of one or two copies of the minor
allele was associated with a later onset of non-mucoid P. aeruginosa with hazard ratios of
0.624 and 0.661 and P-values of 0.039 and 0.068, respectively.
DISCUSSION
This study reports an association between genetic variants of the IL1B gene and lung disease
severity in CF patients. We utilized the cohort from the UNC/CWRU-based, multicenter
study involving 808 ΔF508 homozygote CF patients17 to screen for an association between
lung disease severity and polymorphisms in the IL-1 gene cluster. We initially found an
association in the IL1B gene and lung disease severity. We then sought to replicate this
finding in a different single center using a family-based association analysis: in a subgroup
analysis, our findings are significant in females and suggestive in males based on population
analysis. Collection of study subjects from a single center affords some control over
variation in environmental factors, which are difficult to control in multicenter studies.
Despite the fact that we used a relatively small family-based cohort, we were able to
substantiate the results of the larger case-control study, probably because a single-center
study can have higher power to detect genetic contributions to outcomes that have a
substantial non-genetic component by reducing environmental heterogeneity.31
Replication of associations in multiple independent patient populations using different study
designs is critical in confirming a potential pathologic role for a genetic variant in a disease
process. To our knowledge, two family association (FBAT) studies pertaining to a CF cohort
have been published; neither study explored an association among IL-1 gene polymorphisms
and lung function decline or Pseudomonas acquisition.32,33 We confirmed the association
we found in the case-control analysis, using 126 trios and FBAT, which avoids spurious
associations related to population stratification. In addition to testing an additional cohort to
validate the observed associations in the primary cohort, we undertook the following
measures for validation: population stratification was tested for in the primary cohort and
none was found; only Caucasian subjects were analyzed, so that similarities in the ethnicity
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of the subject and allele frequencies observed in the cohorts suggest adequate genetic
comparability; and adjustments for identical covariates in the analyses ensured
comparability between the cohorts.
Furthermore, our findings are consistent among several phenotypes. We found that IL1B
SNPs rs1143634 and rs1143639 were overrepresented among the CF severity groups in both
the UNC/CWRU and CHB cohorts at a statistically significant level. Specifically in the
analysis of longitudinal changes in lung function, there was a negative relationship between
the number of copies of the minor allele of both SNPs and FEV1% predicted, indicating that
the minor allele is associated with a reduction in this measure of lung function. While
dichotomous pulmonary function severity analysis did not show a consistent association
between the two cohorts, nor were the genetic models consistent, this may be due to the
small sample sizes in the CHB-based gender-stratified analysis. Although we avoid
population stratification and admixture by using the FBAT approach, we lose power because
of homozygous parents who are uninformative. Limiting the study to only ΔF508
homozygotes, as had been done by Drumm and colleagues in the UNC/CWRU cohort,17
likely minimized variability at the CFTR locus and might have contributed to phenotypic
differences. Differing ascertainment schemes of a single-center study versus multicenter
study and diagnostic criteria for defining the dichotomization of pulmonary impairment
categories may also help explain the discrepancy. Yet, despite these limitations, in addition
to showing that variation in the IL1B gene is associated with diminished lung function, we
also found an association between these variants and CF affection status (transmission
distortion). Our hypothesis, supported by the trio data, is that these two SNPs—rs1143634
and rs1143639—are more strongly associated with disease status in the CF cases (the
proband) compared with the controls (their unaffected parents).
The results of the transmission distortion testing (TDT) in the FBAT analysis for affection
status, corrected for multiple comparisons, suggest that these two SNPs are associated with
CF independent of CFTR genotype or could be a surrogate marker of disease severity. A
subgroup analysis suggested that the effect was present only in females, in whom there was
over-transmission of these alleles. In the family-based analysis, the association in females
was observed despite the small number of informative families. In the population-based
analysis, the strength of the association is stronger among females as well (FDR adjusted P
< 0.06 for females for both SNPs). This could be of importance if survival bias allowed for a
protective IL1B allele in males but a non-protective one in females. Earlier acquisition of P.
aeruginosa in CF females has been postulated to contribute to diminished survival.34,35 It is
conceivable that IL-1β release following infectious and other environmental exposures
(influenced by hormones) may occur in a time-dependent manner to affect bacterial
clearance and ultimately disease expression differentially in males and females. The timing
and duration of the infectious and environmental stimuli remain unknown and will be the
basis of future studies.
The IL1B genotype association is consistent with findings related to a role for rapid IL-1β
release in activating innate immunity following binding of P. aeruginosa to WT-CFTR and
gender findings showing a poorer outcome in CF females.34–36 However, the precise
relationship remains unclear. Although the IL1B locus harbors variants that contribute to CF
diagnosis (based on transmission distortion results) as well as lung function decline (based
on longitudinal lung function analysis), the relationship and mechanism are complex. SNP
analyses detected associations between SNPs within exon 5 (rs1143634) and intron 6
(rs1143639) and lung disease severity. While the changes to the nucleotides within the IL1B
gene are synonymous, it is likely that the associations observed are due to strong LD
between associated SNPs and the true phenotype causal variant(s) of lung disease severity in
CF. We speculate that the causative variants may influence lung disease severity by altering
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susceptibility to P. aeruginosa infection. For both rs1143634 and rs1143639, the presence of
one or two copies of the minor allele was associated with later onset of non-mucoid P.
aeruginosa, which is in turn associated with better lung function over the lifetime of CF
patients.35 Thus, early acquisition of P. aeruginosa may be affected, suggested by the
parallel but offset lung function curves depicted in Figures 1 and 2. For patients in our study
with one or two copies of the minor allele and lower FEV1, the IL1B gene polymorphisms
may represent a hyperimmune response that is effective against infection but possibly
destructive to the airway. When evaluating the two SNPs we found to be significant in the
IL1B gene, we detected no relationship between them and acquisition of mucoid P.
aeruginosa. Again, the small number of subjects may explain this. However, these two SNPs
may be influencing lung function in CF subjects by a different mechanism.
Several molecular properties associated with IL-1 release and responses to P. aeruginosa
have been reported. In gene expression microarrays modeling P. aeruginosa infection, IL1B
was increased, suggesting a role for IL-1B in P. aeruginosa acquisition and lung
function.37IL-1β release, binding to the IL-1R, and signaling involving the myd88 adaptor
protein are all needed for rapid NF-κB nuclear translocation following P. aeruginosa
infection in the presence of WT-CFTR.38,39 This process is deficient in cells and mice
lacking WT-CFTR.15 Furthermore, myd88 knockout mice have increased susceptibility to P.
aeruginosa infection.5,40,41 Thus, cellular and animal data suggest a role for CFTR-
dependent IL-1 release and signaling through the IL-1R in modulating resistance to P.
aeruginosa. Another component of CF lung disease that could be affected by IL-1 is the
chronic inflammation that results from P. aeruginosa infection and clearly contributes to
disease pathogenesis. A rapid and early inflammatory response would likely be effective in
clearing P. aeruginosa, whereas a delay, as could occur in CF, would lead to dysregulated
production of IL-1 and pathology from inflammation. In support of this view, neutralization
of IL1B well into the course of an acute lung infection in mice ameliorates pathology and
promotes bacterial clearance. Thus, IL-1-mediated responses to P. aeruginosa could
influence CF lung disease by modulating the early and/or chronic response to infection. The
hypothesis that the innate immune response contributes independently to progression of CF
lung disease, possibly via intrinsic airway inflammation sustained by IL-1β, is also
supported by the recent finding that the antibiotic moxifloxacin, used to treat P. aeruginosa
infection in CF patients, selectively inhibits NF-κB as well as the ERK signaling pathway,
which can also be modulated by IL-1.42
Functional analysis is ongoing to determine whether the significant SNPs we identified
affect IL-1β levels, protein folding, or effectiveness in promoting P. aeruginosa
colonization. Preliminary results suggest that some inflammatory cytokines are produced
and/or released in a CFTR-dependent manner in airway epithelial cells, and proper
production of these proteins is associated with increased resistance to P. aeruginosa
infection.1 Rapid IL-1 release is muted in cells with only ΔF508 CFTR alleles compared
with the same cells with WT-CFTR, but the endogenous levels of IL-1 are comparable in
these cells. However, IL-1 is released from CF airway cells after about 60 minutes of
exposure to P. aeruginosa suggesting that both the timing and amount of IL1β released in
response to Pseudomonas in the lung are critical determinants of rapid bacteria elimination
and resolution of inflammation.1 Furthermore, natural limitations in diffusion of
inflammatory cytokines resulting from proper closing of gap-junctional signaling following
release of cytokines in airway epithelial cells expressing WT-CFTR contribute to the
regulated inflammatory response resulting in elimination of this pathogen in normal lungs.43
Thus, an IL-1 allele in a CF patient resulting in higher endogenous levels of this cytokine in
airway epithelial cells could lead to sufficient, CFTR-independent IL-1 release following P.
aeruginosa to mediate clearance of the microbe in a manner comparable to individuals with
WT-CFTR. Alternatively, an IL-1R allele more responsive to lower levels of IL-1 could also
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induce a more WTinnate immune response in CF patients with such a (hypothetical) allele.
In contrast, a similar situation could also be pathologic, resulting in an increased
inflammatory response if the IL-1R interactions occur later, and other regulatory factors
contributing to CFTR-dependent resolution of inflammation are lacking. Overall,
preliminary results from cell culture, animal, and human genetic studies can be viewed in
the context of an emerging clinical phenotype and its impact on CF lung pathophysiology,
and represent a logical starting point for focused longitudinal genetic studies and functional
analysis. Further studies may yield new insights into the pathogenesis of inflammatory
airway disorders such as CF and reveal new links among the production of IL-1β, the innate
immune response, and P. aeruginosa acquisition.
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Age and gender-adjusted means at each visit representing each of 99 patients once. Plots and
longitudinal analyses were limited to subjects with all five measurements, to limit any
potential cohort effect. a: Fifty-six patients are homozygous major for the GG genotype, and
43 are heterozygous/homozygous minor with either an AG or AA phenotype (rs1143634
without confidence interval shown). b: Fifty-seven patients are homozygous for the major
allele, CC, and42patients are heterozygous/homozygous minor for the CT or TT genotype
(rs1143639 without confidence interval shown).
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a: Fifty-six patients are homozygous major for the GG genotype, and 43 are heterozygous/
homozygous minor with either an AG or AA phenotype (rs1143634 with confidence interval
shown). b: Fifty-seven patients are homozygous for the major allele, CC, and 42 patients are
heterozygous/homozygous minor for the CT or TT genotype (rs1143639 with confidence
interval shown).
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TABLE 1
Characteristics of 808 Patients With Cystic Fibrosis Homozygous for the DF508 Mutation, According to the
Phenotype for Severe or Mild Impairment of Lung Function and Age (Initial Study)
Degree of impairment
Variable Severe, N = 263 Mild, N = 545 P-value
Age (years)
  Range 8–25 15–55
  Mean 16.2 ± 4.1 28.6 ± 9.7 < 0.001
Sex (% male) 49.4 55.6 0.10
FEV1 (% of predicted value) 46.6 ± 16.1 72.4 ± 28.1 < 0.001
FEV1 decline (%/year) 3.65 ± 2.20 1.35 ± 1.51 < 0.001
Median predicted survival (age in year) 31.4 56.6 < 0.001
Body mass index (percentile) 19.6 ± 21.7 44.0 ± 26.1 < 0.001
Positive test for P. aeruginosa (%) 89.0 86.1 0.25
Diabetes mellitus (%) 15.6 24.0 0.006
Asthma (%) 19.4 22.0 0.39
Adapted from N Engl J Med.17
Pulmonary function classifications are described by Schluchter et al.18
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TABLE 6





Time point Beta P-value Beta P-value
All five visits
  Female −7.21 0.06 −7.05 0.06
  Male −3.29 0.32 −4.10 0.29
  Overall −5.17 0.06 −5.27 0.05
All analyses are adjusted for age. Overall analysis is also adjusted for gender.
The overall P-values test whether mean FEV1% predicted differs across the major allele homozygotes versus the heterozygotes and minor allele
homozygotes combined.
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